

02-02-2005

10/536636

15:03:15 02-02-2005 GB0305163

PCT 34 AMDT

JC13 Rec'd PCT/PTO 27 MAY 2005

46

1 Claims

2

3 1. The use of (i) a naked binding member which
4 binds to both SCR1 and SCR2 of CD55 or (ii)
5 a nucleic acid encoding said binding member
6 in the preparation of a medicament for the
7 enhancement of complement deposition on a
8 tissue, wherein the naked binding member is
9 not bound to any agent having anti-tumour
10 properties.

11

12 2. The use of (i) a naked binding member which
13 binds to both SCR1 and SCR2 of CD55 or (ii)
14 a nucleic acid encoding said binding member
15 in the preparation of a medicament for
16 treating cancer, wherein the naked binding
17 member is not bound to any agent having
18 anti-tumour properties.

19

20 3. The use according to claim 2 wherein the
21 cancer is one or more of colorectal, breast
22 , ovarian, cervical, gastric, lung, liver,
23 skin and myeloid (e.g. bone marrow) cancer.

24

25 4. The use according to any one of the
26 preceding claims wherein the binding member
27 is an antibody or a fragment thereof.

28

29 5. The use according to any one of the
30 preceding claims wherein the binding member
31 binds to amino acids 83-93 and SCR2 amino
32 acids 101-112 and amino acids 145-157 of the

AMENDED SHEET

1001 1111 .. /44 P.006

Empf.zeit:02/02/2005 16:06

1 sequences shown in Figure 1b.
2

3 6. The use according to any one of the
4 preceding claims wherein the binding member
5 comprises one or more of the CDRs of the
6 antibody, or a fragment thereof, produced by
7 the cell line deposited at ATCC under
8 accession number HB9173.

9 7. The use according to any one of the
10 preceding claims wherein the binding member
11 is the antibody 791T/36 produced by the
12 hybridoma cell deposited at ATCC under
13 accession number HB9173.

14 8. The use according to any one of claims 1 to
15 7 wherein the binding member comprises at
16 least one human constant region.

17 9. A naked binding member which binds to both
18 SCR1 and SCR2 for use in the treatment of
19 cancer.

20 10. A naked binding member, which binds to both
21 SCR1 and SCR2 of CD55, and an active agent
22 as a combined preparation for simultaneous,
23 separate or sequential use in the treatment
24 of cancer, wherein said active agent is a
25 chemotherapeutic agent, a pain relief agent
26 or an anti-emetic.

27
28
29
30
31

- 1 11. The combined preparation according to claim
2 10, wherein said active agent is a
3 Doxorubicin, taxol, 5-Fluorouracil,
4 Irinotecan or Cisplatin.
- 5
- 6 12. The combined preparation according to claim
7 10 wherein said active agent is an antibody.
- 8
- 9 13. The combined preparation according to claim
10 13 wherein said active agent is an anti-CD20
11 antibody; an anti-VEGF antibody; an anti-
12 CD171A antibody; an anti-CEA anti-idiotypic
13 mAb; an anti-HMFG anti-idiotypic mAb; an
14 anti-EGFR antibody, or an anti-HER2 antibody
15 e.g. Herceptin, Genentech (South San
16 Francisco, CA, USA).
- 17
- 18 14. The naked binding member according to any
19 one of claims 9 to 10, or the combined
20 preparation according to any one of claims
21 11 to 13 wherein the naked binding member is
22 as defined in any one of claims 1 to 8.
- 23
- 24 15. A pharmaceutical composition for the
25 treatment of cancer, wherein the composition
26 comprises a naked binding member that binds
27 to both SCR1 and SCR2 of CD55 and a
28 pharmaceutically acceptable excipient,
29 diluent or carrier.
- 30
- 31 16. The pharmaceutical composition according to
32 claim 15, wherein the naked binding member

- 1 is as defined in any one of claims 1 to 8.
- 2
- 3 17. A method of neutralising the complement
4 activation inhibition activity of CD55,
5 comprising administration of a naked binding
6 member which specifically binds to SCR1 and
7 SCR2 of CD55.
- 8
- 9 18. A method of enhancing complement deposition
10 comprising administration of a naked binding
11 member which specifically binds to SCR1 and
12 SCR2 of CD55.
- 13
- 14 19. A method of treating cancer comprising
15 administration of a therapeutically
16 effective amount of a naked binding member
17 which specifically binds to SCR1 and SCR2 of
18 CD55 to a mammal in need thereof.
- 19
- 20 20. A method according to any one of claims 17
21 to 19 wherein the naked binding member is as
22 defined in any one of claims 1 to 8.
- 23
- 24